4.7 Article

LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation

Journal

ACTA PHARMACEUTICA SINICA B
Volume 12, Issue 9, Pages 3602-3617

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2022.04.006

Keywords

Idiopathic pulmonary; fibrosis; LncRNA DACH1; SRSF1; CTNNB1; Fibroblast; Myofibroblast; Extracellular matrix; Proliferation

Funding

  1. National Natural Science Foundation of China [32171127, 91949109]
  2. HMU Marshal Initiative Funding [HMUMIF-21023]
  3. Major Scientific Fund Project of Heilongjiang Province [ZD2019H001]
  4. CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M5-078]
  5. Guangdong Province Basic and Applied Basic Research Fund [2021A1515111049]
  6. Postgraduate Research and Practice Innovation Program of HMU [YJSCX202015HYD]

Ask authors/readers for more resources

This study found that lncRNA DACH1 is downregulated in patients with pulmonary fibrosis and in a mouse model of the disease. LncDACH1 inhibits lung fibrosis by interacting with SRSF1 to suppress CTNNB1 accumulation.
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with unknown etiology and limited therapeutic options. Activation of fibroblasts is a prominent feature of pulmonary fibrosis. Here we report that lncRNA DACH1 (dachshund homolog 1) is downregulated in the lungs of IPF patients and in an experimental mouse model of lung fibrosis. LncDACH1 knockout mice develop spontaneous pulmonary fibrosis, whereas overexpression of LncDACH1 attenuated TGF-beta 1-induced aberrant activation,collagen deposition and differentiation of mouse lung fibroblasts. Similarly, forced expression of LncDACH1 not only prevented bleomycin (BLM)-induced lung fibrosis, but also reversed established lung fibrosis in a BLM model. Mechanistically, LncDACH1 binding to the serine/arginine-rich splicing factor 1 (SRSF1) protein decreases its activity and inhibits the accumulation of Ctnnb1. Enhanced expression of SRSF1 blocked the anti-fibrotic effect of LncDACH1 in lung fibroblasts. Furthermore, loss of LncDACH1 promoted proliferation, differentiation, and extracellular matrix (ECM) deposition in mouse lung fibroblasts, whereas such effects were abolished by silencing of Ctnnb1. In addition, a conserved fragment of LncDACH1 alleviated hyperproliferation, ECM deposition and differentiation of MRC-5 cells driven by TGF-beta 1. Collectively, LncDACH1 inhibits lung fibrosis by interacting with SRSF1 to suppress CTNNB1 accumulation, suggesting that LncDACH1 might be a potential therapeutic target for pulmonary fibrosis. (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available